U.S. Obesity Market Analysis: Exploring Demographic & Geographic Disparities in GLP-1 Use

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective treatment options for obesity. Medications such as semaglutide (branded as Ozempic and Wegovy) and tirzepatide (branded as Mounjaro and Zepbound) work by mimicking a…